Reviewer
Reviewer
Reviewer
Anticoagulant agents
1. Vitamin K reductase inhibitors- WI
coumarin derivative warfarin (Coumadin) or
the indandione analog anisindione (Miradon).
substitutions at position 3 and 4 with the potential to form a cyclic hemiketal
therapeutic benefits are observed in 3 to 4 days.
CYP2C9 (which metabolizes warfarin)
Warfarin is used to treat deep vein thrombosis, pulmonary embolism, and clots due to
atrial arrhythmias and prosthetic cardiac valves.
Bleeding, skin necrosis, purple toe syndrome, and alopecia are observed; birth defects are
likely if taken during pregnancy.
2. Unfractionated and low-molecular-weight heparins.
Unfractionated heparins (UFHs) are mucopolysaccharide polymers (60 to 100 kDa;
extracted from mast cells of bovine lung tissue or porcine intestinal mucosa.
Low-molecular-weight (LMWHs, 2 to 10 kDa) are produced by careful fragmentation of
UFH and purification by gel filtration to produce agents such as: TED
o enoxaparin (Lovenox), tinzaparin (Innohep), and dalteparin (Fragmin).
o UFHs have high affinity for antithrombin III (AT-III) and catalyze the
inactivation of factor Xa and IIa by AT-III,
o LMWHs also bind to AT-III
Both UFHs and LMWHs IV and SC
LMWHs with longer half-life.
These agents are used for pulmonary emboli prophylaxis and to treat venous
thromboemboli until transitioned to warfarin.
Fondaparinux (Arixtra) is a synthetic pentasaccharide that inhibits factor Xa through
the action of AT-III.
Danaparoid (Orgaran) is a mixture of heparin sulfate, dermatan sulfate, and
chondroitin sulfate extracted from porcine mucosa and having a similar mechanism of
action as LMWHs.
Adverse effects related to heparin use are bleeding, heparin-induced thrombocytopenia
(HIT), alopecia, and osteoporosis.
Overdose treated protamine sulfate that neutralizes the polysaccharides via ionic
interaction.
3. Direct thrombin inhibitors BLAD
the catalytic or substrate recognition site of the protease without the need for AT-III.
Lepirudin (Refl udan) is a 65 amino acid recombinant derivative of hirudin, the
anticoagulant found in the saliva of the medicinal leech.
Bivalirudin (Angiomax) is a synthetic 20 amino acid derivative of hirudin.
Argatroban is also a parenterally administered, direct thrombin inhibitor, and all three of
these agents are used to treat HIT.
Dabigatran (Pradaxa) is the first orally active direct thrombin inhibitor and is used to
prevent stroke in patients with atrial fibrillation.
ADR: bleeding, but dabigatran is also associated with GI disturbances such as
esophageal reflux, gastric bleeding, and abdominal pain.
H. Antiplatelet agents ACD TCP TAE
1. Aspirin.
cyclooxygenase ,reduces the amount of thromboxane
Aspirin is used for the prophylaxis of myocardial infarctions and, in conjunction with
other agents, it decreases thrombosis aft er coronary stenting.
2. Dipyridamole (Persantine) and cilostazol (Pletaal)
stroke prophylaxis in cerebrovascular ischemia or after prosthetic valve replacement.
Cilostazol is also used for intermittent claudication.
3. Thienopyridines
Ticlopidine (Ticlid), clopidogrel (Plavix), and prasugrel (Effient;)
bioactivated by hepatic CYP enzymes before they are active.
bind to the P2Y12 receptors on
These drugs are used to decrease clot formation after angioplasty and stenting
procedures and are often combined with aspirin or GPIIb/IIIa inhibitors.
The following adverse effects are rare but can be serious: thrombocytopenia purpura,
aplastic anemia, neutropenia, cholestatic jaundice, fever, rash, and GI distress
4. Glycoprotein IIb/IIIa inhibitors
abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat).
decreased platelet aggregation during clot formation and reduced thrombus size.
Abciximab is the Fab fragment of a monoclonal antibody
I. Thrombolytic agents TASU
1. Tissue plasminogen activators (tPAs) are normally released by endothelial cells to activate
fibrin-bound plasminogen to plasmin. Plasmin then cleaves fibrin strands to cause the
disintegration of the clot.
Human tPA, alteplase (Activase)
Tenecteplase (Tnkase) is also a mutant of tPA designed to have enhanced fibrin
selectivity.
Their primary adverse effect is risk of bleeding, and this can be managed by the
administration of aminocaproic acid (Amicar).
2. Streptokinase (Streptase)
is a 47 kDa protein.
does not require the presence of fibrin to activate plasminogen
3. Urokinase (Abbokinase)
serine protease
Oral factor Xa inhibitor
Direct factor Xa inhibitor (rivaroxaban [Xarelto])
Oral direct thrombin inhibitor
Direct factor IIa (thrombin) inhibitor (dabigatran [Pradaxa])
Heparin
rapid-acting anticoagulant , administered parenterally.
Standard heparin (unfractionated heparin [UFH]) is a heterogeneous mixture of
glycosaminoglycans
Binds to antithrombin (AT)or heparin cofactor which accelerates the anticoagulant effect
of AT. irreversibly inactivates factor IIa (thrombin) and factor Xa
inhibits platelet function and increases vascular permeability
(IV) by continuous infusion, or subcutaneously (SC), IM cause hematoma
After IV administration, the anticoagulant effect of heparin is noted immediately.
Monitor activated partial thromboplastin time(APPT)
SE: osteoporosis, hypersensitivity, hyperkalemia
Low-Molecular-Weight Heparins TED, 2-10 kDA
dalteparin (Fragmin),
enoxaparin (Lovenox),
tinzaparin (Innohep).
inactivate factor Xa
the anti-Xa properties of LMWHs are more significant than their anti-IIa properties.
Hct, INR, renal function, and platelet count should be determined.
Advantages
Does not require aPTT monitoring for therapeutic effect
reduced binding affinity for plasma proteins and endothelial cells
UFH 60-100 kDA
renally compromised
pregnant women
Fondaparinux (Arixtra)
is a selective indirect factor Xa inhibitor
prevention of venous thrombosis associated with orthopedic surgery and abdominal
surgery,
for the treatment of DVT and pulmonary embolism.
inactivate factor Xa with no direct impact on factor IIa.
This agent has a long elimination half-life, OD SC at a fixed dose without the need for
routine coagulation monitoring.
Renal excretion!
Direct Thrombin Inhibitors BLAD
Argatroban, (liver)
lepirudin (Refludan), (renal)
bivalirudin (Angiomax) (renal)
dabigatran( pradaxa)
Continuous infusion and require aPTT monitoring for appropriate dosing adjustments.
Bivalirudin is also used in patients undergoing percutaneous coronary intervention.
Warfarin
oral anticoagulant with a delayed onset of effect
vitamin K antagonist
Vitamin K is essential for the conversion (carboxylation) of precursors to clotting factors
II, VII, IX, and X into inactive clotting factors and for the synthesis of protein C and
protein S.
It takes approximately 5 to 7 days to reach a steady state
Protein C and its cofactor protein S are also vitamin K dependent, and are depleted by
warfarin. Warfarin is rapidly and completely absorbed in the upper gastrointestinal (GI)
tract by passive diffusion, with nearly 100% bioavailability.
It is approximately 99% bound to serum albumin.
(Vd) for warfarin is 12.5% of body weight.
Monitor the prothrombin time (PT).
warfarin is metabolized by primarily by CYP1A2 and CYP3A4.
CYP2C9 (kidney) influences the rate of metabolism of warfarin and thus impacts dosing
requirements
ADR: hemorrhage, skin necrosis, purple toe
Chronic Alcohol ingestion induce metabolization , inc dose
Acute alcohol ingestion, inc bleeding
Tests Used to Monitor Antithrombotic Therapy
Before the initiation of antithrombotic therapy, obtain a baseline platelet count and
hematocrit (Hct),
PT and aPTT, the tests used to monitor warfarin and heparin, respectively.
Prothrombin Time/International Normalized Ratio
It reflects alterations in the extrinsic pathway
INR is the standard for monitoring warfarin therapy
prolonged by deficiencies of clotting factors II, V, VII, and X, low levels of fibrinogen
and very high levels of heparin.
The PT is measured by adding calcium and tissue thromboplastin
The ISI of the international reference thromboplastin is 1.0.
Regular intensity therapy INR goal is 2.5 (range, 2.03.0)
High-intensity therapy INR goal of 3.0 (range, 2.53.5).
Activated Partial Thromboplastin Time
The aPTT reflects alterations in the intrinsic pathway